Morningstar

Vaxcyte Inc Ordinary Shares PCVX

Morningstar Rating

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire Sep 11, 2024 8:05pm
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire Sep 6, 2024 8:05pm
Vaxcyte's stock flat as biotech preps to complete $1.42 billion stock offering

MarketWatch Sep 6, 2024 4:48pm
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

GlobeNewswire Sep 5, 2024 3:58am
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire Sep 3, 2024 8:01pm
Vaxcyte's stock soars 42% to record high after trial shows positive data for pneumococcal vaccine

MarketWatch Sep 3, 2024 1:39pm
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

GlobeNewswire Sep 3, 2024 11:07am
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

GlobeNewswire Sep 2, 2024 10:40pm
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)

PR Newswire Aug 26, 2024 5:30pm
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire Aug 6, 2024 8:05pm
Vaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine Application

Global News Select Oct 19, 2023 1:14pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.